Skip to content
TriangleGet started
← Full study record

NCT03157128 · OUTCOME

Phase 1: Recommended Phase 2 Dose (RP2D)

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) · Source last updated 2026-04-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
milligrams
Interval / dispersion
Not reported
Time frame
Cycle 1 (cycle length = 28 days)

What was measured

Phase 1: RP2D

Analysis population: All Participants who received at least 1 or more doses of selpercatinib and had evaluable data for this outcome.

Groups in this outcome

Phase 1 - Selpercatinib (All Participants)

All Phase 1 Participants who received Selpercatinib (20 mg - 240 mg) orally once daily (QD) or twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase 1 - Selpercatinib (All Participants)827

Reported measurements

Source class 1
Values in milligrams · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Phase 1 - Selpercatinib (All Participants)160Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        160
denoms
  1. counts
    1. group Id
      OG000
      value
      827
    units
    Participants
description
Phase 1: RP2D
groups
  1. description
    All Phase 1 Participants who received Selpercatinib (20 mg - 240 mg) orally once daily (QD) or twice daily (BID), in a 28-day treatment cycle. Treatment was continued until disease progression, unacceptable toxicity, or treatment discontinuation for other reasons.
    id
    OG000
    title
    Phase 1 - Selpercatinib (All Participants)
param Type
NUMBER
population Description
All Participants who received at least 1 or more doses of selpercatinib and had evaluable data for this outcome.
reporting Status
POSTED
time Frame
Cycle 1 (cycle length = 28 days)
title
Phase 1: Recommended Phase 2 Dose (RP2D)
type
PRIMARY
unit Of Measure
milligrams

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice